Fate Of JHL Biotech's Biosimilars Uncertain As Judge Bars Use Of Genentech Trade Secrets
Court denies JHL motion to dismiss trade secret theft suit, bars development or sale of biosimilars that rely on information from Genentech documents; trial scheduled to begin in November 2020.
You may also be interested in...
Alvotech has issued a robust rebuttal of accusations that it obtained AbbVie trade secrets relating to Humira for use in developing its biosimilar adalimumab rival.
AbbVie claims a former employee took Humira manufacturing process know-how to Alvotech. Settlement is likely as Alvotech does not want to delay development of its biosimilar and AbbVie doses not want to disclose its trade secrets in court.
Genentech reaches memorandum of understanding with JHL Biotech involving four biosimilars while continuing its suit against former employees; Amgen settlement with Coherus ended litigation entirely.